FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab
If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.
Exploring issues and controversies in the relationship between science and medicine
If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.